Impact of Radicality Versus Timing of Surgery in Patients with Advanced Ovarian Cancer (Stage III C) Undergoing CRS and HIPEC—a Retrospective Study by INDEPSO-Reference-Cited by-同舟云学术

Impact of Radicality Versus Timing of Surgery in Patients with Advanced Ovarian Cancer (Stage III C) Undergoing CRS and HIPEC—a Retrospective Study by INDEPSO

Published:2019-01-16 Issue:S1 Volume:10 Page:57-64
ISSN:0975-7651
Container-title:Indian Journal of Surgical Oncology
language:en
Short-container-title:Indian J Surg Oncol

Author:

Bhatt Aditi^ORCID,Sinukumar Snita,Rajan Firoz,Damodaran Dileep,Ray Mukurdipi,Zaveri Shabber,Kammar Praveen,Mehta Sanket

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/article/10.1007/s13193-019-00875-z/fulltext.html

Reference28 articles.

1. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371–1382. https://doi.org/10.1016/S0140-6736(09)61338-6

2. Bhatt A, Glehen O (2016) the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (hipec) in ovarian cancer: a review. Indian J Surg Oncol 7(2):188–197. https://doi.org/10.1007/s13193-016-0501-9

3. Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O (2014) Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg 151:347–353. https://doi.org/10.1016/j.jviscsurg.2014.07.005

4. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240

5. Chi DS, Bristow RE, Armstrong DK, Karlan BY (2011) Is the easier way ever the better way? J Clin Oncol 29:4073–4075

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological PCI as a prognostic marker of survival after neoadjuvant chemotherapy in patients undergoing interval cytoreduction with or without HIPEC in FIGO stage IIIC high grade serous ovarian cancer;Frontiers in Oncology;2024-08-20

2. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the management of peritoneal surface malignancies – An evidence-based review;Current Problems in Cancer;2021-12

3. Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients;Future Oncology;2021-09

4. Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications;European Journal of Surgical Oncology;2021-01

5. The Role of CRS and HIPEC in Ovarian Cancer;Multidisciplinary Approach to Surgical Oncology Patients;2021